




RealRate

PHARMACEUTICAL 2022

NextCure Inc.
Rank 161 of 475

NextCure



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2022

NextCure Inc.
Rank 161 of 475



The relative strengths and weaknesses of NextCure Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NextCure Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 195% points. The greatest weakness of NextCure Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is -22%, being 254% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	227,817
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,608
Liabilities, Non-Current	0
Other Assets	577
Other Compr. Net Income	-1,442
Other Expenses	0
Other Liabilities	2,392
Other Net Income	1,376
Property and Equipment	13,992
Research and Development	50,192
Revenues	0
Selling, General and Administrative Expense	20,573

Output Variable	Value in 1000 USD
Assets	242,386
Liabilities	9,000
Expenses	70,765
Stockholders Equity	233,386
Net Income	-69,389
Comprehensive Net Income	-70,110
Economic Capital Ratio	-22%

